ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...